Privacy settings

Utilizziamo cookies tecnici, necessari per il corretto funzionamento del sito, cookies statistici e cookies di marketing (inclusi cookies di terze parti), al fine di mostrarti offerte e pubblicità basate sui tuoi gusti e preferenze. Per maggiori informazioni puoi consultare la nostra Privacy Policy. I cookies statistici e i cookies di marketing (inclusi cookies di terze parti) sono utilizzati esclusivamente con il tuo consenso. Cliccando “Seleziona tutto e acconsenti” consenti il trattamento dei cookies statistici e di marketing (inclusi cookies di terze parti).

Cliccando “Rifiuta tutto”, rimarranno attive le impostazioni di default del sito (ossia verranno utilizzati esclusivamente cookie tecnici necessari per la navigazione).

Per personalizzare le tue impostazioni privacy, seleziona le tue preferenze tra le caselle qui sotto e clicca “Applica la selezione”. Ti ricordiamo per puoi modificare le tue impostazioni privacy in qualsiasi momento e disattivare i cookies, seguendo le istruzioni riportate nella Privacy Policy.

Deny all Show preferences Select all and accept
IMA is loading

IMA’s way to Continuous Manufacturing

IMA Active is now ready for the paradigm shift in pharmaceutical manufacturing and taking the lead in the future of pharmaceutical technologies for OSD forms.
IMA Active’s belief in and knowledge of Continuous Manufacturing have grown stronger thanks to intensive R&D work carried out on two fronts.

A more disruptive front of IMA Active R&D consists in the partnership with CONTINUUS Pharmaceuticals, a spin out of Novartis-MIT Centre, leveraging a novel production platform called Integrated Continuous Manufacturing (ICM). ICM enables seamless end-to-end Continuous Manufacturing processes that incorporate API formation steps with final drug product formulation.
IMA Active supports ICM in the development of EMC (Extrusion Molding Coating) technology to create the final dosage form.

While on the other R&D front IMA Active works on continuous processes by revisiting current technologies, embracing a concept of Continuous Manufacturing more closely related to conventional solid forms.

This initiative aims primarily to introduce continuous equipment into the market that can be integrated with conventional technologies, even in an existing plant, in order to improve the production performance of existing drugs.

Discover how to improve your production with Continuous Manufacturing.